
Alexis Borisy
Alexis Borisy is a Boston biotech founder who co-founded Foundation Medicine, which Roche bought out in 2018 at a $5.3B value, and Blueprint Medicines, which Sanofi bought for up to $9.5B in 2025. He now runs Curie.Bio and chairs Relay Therapeutics.
- Education
- The University of Chicago, Harvard University
Track record
Companies Alexis Borisy founded or backed, with what became of them.
- CCombinatoRxFounder and CEO 2000–2009Listed on Nasdaq
Foundation MedicineCo-founder, first CEO, then chairmanBought out by Roche in 2018 at a $5.3B value
Blueprint MedicinesCo-founded in 2011; interim CEO 2013–2014Bought by Sanofi for up to $9.5B in 2025
EQRxFounder, CEO and chairman from 2019Bought by Revolution Medicines in 2023
IDRxCo-founded in 2022Bought by GSK for up to $1.15B in 2025
Relay TherapeuticsFounding investor, former CEO, now chairmanListed on Nasdaq in 2020
Editas MedicineFounding investor at Third Rock VenturesListed on Nasdaq in 2016
Curie.Bio
Career
- 2000Founds CombinatoRx and runs it as CEO, later taking it public on Nasdaq.
- 2010Joins Third Rock Ventures as a partner and co-founds Foundation Medicine.
- 2011Co-founds Blueprint Medicines and joins its board.
- 2018Roche buys the rest of Foundation Medicine for $2.4B, valuing it at $5.3B.
- 2019Leaves Third Rock and founds EQRx to make lower-priced drugs.
- 2022Co-founds IDRx and Curie.Bio.
- 2023Revolution Medicines buys EQRx and winds down its drug programmes.
- 2025GSK buys IDRx for up to $1.15B. Sanofi buys Blueprint Medicines for up to $9.5B.
Sources: Alexis Borisy, Relay Therapeutics · Alexis Borisy, Blueprint Medicines · Roche buys Foundation Medicine for $2.4B (Medical Xpress, 2018) · Revolution Medicines completes acquisition of EQRx · GSK completes $1.15B acquisition of IDRx (DCAT) · Alexis Borisy, Dealroom.
Companies founded







Currently
Active roles, board seats and partnerships.
Work history
Past roles by Dealroom records.
Education







